CCP
DNLI icon

Clough Capital Partners’s Denali Therapeutics DNLI Stock Holding History

Clough Capital Partners’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-51,830
Closed -$856K – 103
2025
Q4 		$856K Buy
+51,830
New +$875K 0.08% 103

Other funds holding DNLI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Clough Capital Partners's DNLI Position: Q1 2026 in Review

Clough Capital Partners sold out of Denali Therapeutics (DNLI) in Q1 2026, closing a stake of 51,830 shares — an estimated $856K sold.

Clough Capital Partners first reported a position in DNLI in Q4 2025 and held it in 1 quarter. The position peaked at $856K in Q4 2025. 268 funds tracked by Wall St. Rank hold DNLI as of Q1 2026.

  • Clough Capital Partners reported no remaining Denali Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Clough Capital Partners sold 51,830 Denali Therapeutics shares in Q1 2026, an estimated $856K.
  • Clough Capital Partners first reported a position in Denali Therapeutics in Q4 2025 and held it in 1 quarter.
  • Clough Capital Partners's Denali Therapeutics position peaked at $856K in Q4 2025.
  • 268 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2026.

Based on Clough Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.